PHASIFY™ sample preparation can be
applied to any sample type, including
blood, saliva, urine, and water.

CANCER
DIAGNOSTICS
INFECTIOUS DISEASE
TESTING
NON-INVASIVE PRENATAL
TESTING

FOCUS AREAS

Liquid biopsy allows clinicians to collect blood samples for diagnostic purposes rather than taking tissue samples from the body.
FOCUS AREA

LIQUID
BIOPSY

 

LATE-STAGE
CANCER SCREENING AND
NON-INVASIVE PRENATAL
TESTS

At present, liquid biopsy is widely applied in late-stage cancer therapy selection and non-invasive prenatal tests. By enhancing sample quality, PHASIFY™ increases the sensitivity of these tests while reducing costs.

EARLY-STAGE
CANCER SCREENING

Research efforts aimed at implementing liquid biopsy for early-stage cancer screening must overcome the challenge of detecting low-concentration tumor DNA fragments.

By concentrating and purifying DNA from blood samples, PHASIFY™ can improve the identification of low frequency cancer mutations.

In so doing, our technology may help to realize the promise of liquid biopsy for early-stage cancer screening.

Phase Scientific has developed an end-to-end
diagnostic solution for accurate COVID-19
testing.
FOCUS AREA

COVID-19
Testing

 

MOLECULAR AND
POINT-OF-CARE TESTS TO
SUPPORT THE SCREENING,
DIAGNOSIS AND MONITORING
OF COVID-19

Phase Scientific has developed tests that are capable of detecting infection at various stages, from early exposure to after you’ve been infected. By knowing who is exposed, the more we can help contain the spread of COVID-19.

Moving diagnostic testing from the laboratory to point-of-care will transform the rate and quantity of testing performed.
FOCUS AREA

Point-of-Care
Tests